<code id='AF1E130A7B'></code><style id='AF1E130A7B'></style>
    • <acronym id='AF1E130A7B'></acronym>
      <center id='AF1E130A7B'><center id='AF1E130A7B'><tfoot id='AF1E130A7B'></tfoot></center><abbr id='AF1E130A7B'><dir id='AF1E130A7B'><tfoot id='AF1E130A7B'></tfoot><noframes id='AF1E130A7B'>

    • <optgroup id='AF1E130A7B'><strike id='AF1E130A7B'><sup id='AF1E130A7B'></sup></strike><code id='AF1E130A7B'></code></optgroup>
        1. <b id='AF1E130A7B'><label id='AF1E130A7B'><select id='AF1E130A7B'><dt id='AF1E130A7B'><span id='AF1E130A7B'></span></dt></select></label></b><u id='AF1E130A7B'></u>
          <i id='AF1E130A7B'><strike id='AF1E130A7B'><tt id='AF1E130A7B'><pre id='AF1E130A7B'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:fashion    - browse:661

          Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

          Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

          advertisement

          You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          hotspot